Literature DB >> 12130707

A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Jeffrey M Brown1, Evan L Riddle, Verónica Sandoval, Raul K Weston, Jarom E Hanson, Michael J Crosby, Yvette V Ugarte, James W Gibb, Glen R Hanson, Annette E Fleckenstein.   

Abstract

Recent studies demonstrated that vesicular dopamine (DA) uptake can be rapidly altered in synaptic vesicles purified from the striata of stimulant-treated rats. Specifically, a single administration of the plasmalemmal DA transporter inhibitor, cocaine, or the DA D(2) agonist, quinpirole, increases vesicular DA uptake in vesicles purified from the striata of treated rats. These effects of cocaine are prevented by pretreatment with a D(2), but not D(1), DA receptor antagonist. The purpose of the present study was to characterize the effect of a mechanistically different psychostimulant, methamphetamine (METH), on vesicular DA uptake. Results demonstrated that a single administration of this DA-releasing agent rapidly and reversibly decreased vesicular DA uptake. The METH-related decrease in vesicular DA uptake was attenuated by pretreatment with the D(2) antagonist, eticlopride, but not the D(1) antagonist, SCH23390 (R-[+]-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine). Core body temperature did not contribute to the effects of METH on vesicular DA uptake. Neither quinpirole nor cocaine increased vesicular DA uptake when rats were concurrently treated with METH. These studies provide further evidence that psychostimulants rapidly and differentially modify vesicular DA uptake. In addition, these studies demonstrate a complex role for D(2) DA receptors in altering vesicular DA transport.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130707     DOI: 10.1124/jpet.302.2.497

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

Review 2.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 3.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.

Authors:  Evan L Riddle; Annette E Fleckenstein; Glen R Hanson
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

4.  Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.

Authors:  Julie Lotharius; Jeppe Falsig; Johan van Beek; Sarah Payne; Ralf Dringen; Patrik Brundin; Marcel Leist
Journal:  J Neurosci       Date:  2005-07-06       Impact factor: 6.167

5.  Methamphetamine self-administration acutely decreases monoaminergic transporter function.

Authors:  Lisa M McFadden; Kristen A Stout; Paula L Vieira-Brock; Scott C Allen; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2011-12-13       Impact factor: 2.562

6.  Peripheral ammonia as a mediator of methamphetamine neurotoxicity.

Authors:  Laura E Halpin; Bryan K Yamamoto
Journal:  J Neurosci       Date:  2012-09-19       Impact factor: 6.167

Review 7.  Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Authors:  Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Journal:  Neuropharmacology       Date:  2008-07-10       Impact factor: 5.250

Review 8.  Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.

Authors:  Kurt F Hauser; Pamela E Knapp
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

9.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

10.  Differential regional effects of methamphetamine on dopamine transport.

Authors:  Pei-Wen Chu; Kristi S Seferian; Elisabeth Birdsall; Jannine G Truong; James A Riordan; Cameron S Metcalf; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2008-05-28       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.